Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Predictors of Positive Bone Metastasis in Newly Diagnosed Prostate Cancer Patients

  • Chien, Tsu-Ming (Department of Urology, Kaohsiung Medical University Hospital) ;
  • Lu, Yen-Man (Department of Urology, Kaohsiung Medical University Hospital) ;
  • Geng, Jiun-Hung (Department of Urology, Kaohsiung Medical University Hospital) ;
  • Huang, Tsung-Yi (Department of Urology, Kaohsiung Medical University Hospital) ;
  • Ke, Hung-Lung (Department of Urology, Kaohsiung Medical University Hospital) ;
  • Huang, Chun-Nung (Department of Urology, Kaohsiung Medical University Hospital) ;
  • Li, Ching-Chia (Department of Urology, Kaohsiung Medical University Hospital) ;
  • Chou, Yii-Her (Department of Urology, Kaohsiung Medical University Hospital) ;
  • Wu, Wen-Jeng (Department of Urology, Kaohsiung Medical University Hospital) ;
  • Huang, Shu-Pin (Department of Urology, Kaohsiung Medical University Hospital)
  • Published : 2016.04.11
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The prevalence of prostate cancer (PCa) has been increasing in recent years. Treatment strategies are largely based on the results of bone scan screening. Therefore, our aim was to investigate predictors of positive bone metastasis in newly diagnosed PCa patients. Materials and Methods: After extensive review, 336 consecutive patients newly diagnosed with PCa between April 2010 and November 2013 at our institution were enlisted in the study. Patients were divided into two groups according to bone scan results. Univariate analyses (Chi-square test for discrete variables and independent t-test for continuous variables) were applied to determine the potentially significant risk factors associated with distant bone metastasis. Binary logistic regression analyses were used to further investigate the influence of these factors on bone metastasis. Results: The patient mean age was $71.9{\pm}8.6years$ (range: 48 to 94 years). The mean prostate specific antigen (PSA) level and biopsy Gleason score were $260.2{\pm}1107.8ng/mL$ and $7.4{\pm}1.5$, respectively. The body mass index (BMI) for the series was $24.5{\pm}3.4kg/m^2$. Sixty-four patients (19.0%) had a positive bone scan result. Patients with positive bone scan results had a significantly lower BMI ($23.3{\pm}3.5$ vs. $24.8{\pm}3.3$; p=0.003), a higher Gleason score ($8.5{\pm}1.1$ vs. $7.1{\pm}1.5$; p < 0.001), and a higher PSA level ($1071.3{\pm}2337.1$ vs. $69.4{\pm}235.5$; p < 0.001) than those without bone metastasis. Multivariate logistic regression analysis employing the above independent predictors demonstrated that a Gleason score of ${\geq}7$, clinical stage ${\geq}T3$, $BMI{\leq}22kg/m^2$, and an initial PSA level of ${\geq}20ng/mL$ were all independent predictors of bone metastasis. Conclusions: A bone scan might be necessary in newly diagnosed PCa patients with any of the following criteria: clinical stage T3 or higher, a Gleason score of 7 or higher, BMI equal to or less than 22, and a PSA level of 20 or higher.

Keywords

References

  1. Bashir MN, Ahmad MR, Malik A (2014). Risk factors of prostate cancer: a case-control study in Faisalabad, Pakistan. Asian Pac J Cancer Prev, 15, 10237-40.
  2. Briganti A, Passoni N, Ferrari M, et al (2010). When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol, 57, 551-8. https://doi.org/10.1016/j.eururo.2009.12.023
  3. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007). Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol, 178, S14-9. https://doi.org/10.1016/j.juro.2007.04.012
  4. Dennis ER, Jia X, Mezheritskiy IS, et al (2012). Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol, 30, 519-24. https://doi.org/10.1200/JCO.2011.36.5791
  5. Drzymalski DM, Oh WK, Werner L, et al (2010). Predictors of survival in patients with prostate cancer and spinal metastasis. presented at the 2009 joint spine section meeting. clinical article. J Neurosurg Spine, 13, 789-94. https://doi.org/10.3171/2010.6.SPINE10167
  6. Falchook AD, Salloum RG, Hendrix LH, Chen RC (2014). Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int J Radiat Oncol Biol Phys, 89, 243-8. https://doi.org/10.1016/j.ijrobp.2013.10.023
  7. Greene KL, Albertsen PC, Babaian RJ, et al (2009). Prostate specific antigen best practice statement: 2009 update. J Urol, 182, 2232-41. https://doi.org/10.1016/j.juro.2009.07.093
  8. Harada M, Iida M, Yamaguchi M, Shida K (1992). Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol, 324, 173-82. https://doi.org/10.1007/978-1-4615-3398-6_18
  9. He D, Wang M, Chen X, et al (2004). Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population. Urol, 63, 722-6. https://doi.org/10.1016/j.urology.2003.10.066
  10. Heidenreich A, Bastian PJ, Bellmunt J, et al (2014). European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol, 65, 124-37. https://doi.org/10.1016/j.eururo.2013.09.046
  11. Hu MB, Liu SH, Jiang HW, Bai PD, Ding Q (2014). Obesity affects the biopsy-mediated detection of prostate cancer, particularly high-grade prostate cancer: a dose-response meta-analysis of 29,464 patients. PLoS One, 9, 106677. https://doi.org/10.1371/journal.pone.0106677
  12. Imbriaco M, Larson SM, Yeung HW, et al (1998). A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res, 4, 1765-72.
  13. Isom-Batz G, Bianco FJ Jr, Kattan MW, et al (2005). Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol, 173, 1935-7. https://doi.org/10.1097/01.ju.0000158040.33531.e7
  14. Kosuda S, Yoshimura I, Aizawa T, et al (2002). Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer, 94, 964-72. https://doi.org/10.1002/cncr.10340
  15. Lee N, Fawaaz R, Olsson CA, et al (2000). Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys, 48, 1443-6. https://doi.org/10.1016/S0360-3016(00)00785-9
  16. Logothetis CJ, Lin SH (2005). Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer, 5, 21-8. https://doi.org/10.1038/nrc1528
  17. Morgentaler A, Bruning CO 3rd, DeWolf WC (1996). Occult prostate cancer in men with low serum testosterone levels. JAMA, 276, 1904-6. https://doi.org/10.1001/jama.1996.03540230054035
  18. Nakashima J, Tachibana M, Ueno M, et al (1998). Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res, 4, 1743-8
  19. Nandeesha H (2009). Insulin: a novel agent in the pathogenesis of prostate cancer. Int Urol Nephrol, 41, 267-72. https://doi.org/10.1007/s11255-008-9440-x
  20. National Comprehensive Cancer Network Guidelines (2014). Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
  21. Oesterling JE, Kumamoto Y, Tsukamoto T, et al (1995). Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol, 75, 347-53. https://doi.org/10.1111/j.1464-410X.1995.tb07347.x
  22. Ost P, Decaestecker K, Lambert B, et al (2014). Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate, 74, 297-305. https://doi.org/10.1002/pros.22750
  23. Pound CR, Partin AW, Eisenberger MA, et al (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281, 1591-7. https://doi.org/10.1001/jama.281.17.1591
  24. Sabbatini P, Larson SM, Kremer A, et al (1999). Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol, 17, 948-57. https://doi.org/10.1200/JCO.1999.17.3.948
  25. Schweizer MT, Zhou XC, Wang H, et al (2013). Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol, 24, 2881-6. https://doi.org/10.1093/annonc/mdt335
  26. Singh D, Yi WS, Brasacchio RA, et al (2004). Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys, 58, 3-10. https://doi.org/10.1016/S0360-3016(03)01442-1
  27. Soloway MS, Hardeman SW, Hickey D, et al (1988). Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61, 195-202. https://doi.org/10.1002/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y
  28. Tanaka N, Fujimoto K, Shinkai T, et al (2011). Bone scan can be spared in asymptomatic prostate cancer patients with PSA of ${\leq}20$ ng/ml and Gleason score of ${\leq}6$ at the initial stage of diagnosis. Jpn J Clin Oncol, 41, 1209-13. https://doi.org/10.1093/jjco/hyr118
  29. Young CY, Montgomery BT, Andrews PE, et al (1991). Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res, 51, 3748-52.

Cited by

  1. Acupuncture for pain caused by prostate cancer vol.98, pp.2, 2019, https://doi.org/10.1097/MD.0000000000013954